Declining nicotinamide adenine dinucleotide (NAD+) has emerged as a recurring signature across failing and aging hearts, but the research question is whether that decline is a bystander or a driver. This review surveys the human observational data and the preclinical loss- and gain-of-function experiments that investigators use to interrogate causality, framed strictly for laboratory research.

Why NAD+ homeostasis is studied in the cardiovascular system

NAD+ occupies an unusual position in cell biology: it is simultaneously a redox cofactor for hundreds of dehydrogenases and a consumable substrate for signaling enzymes that cleave it. The adult heart is among the most energy-demanding tissues in the body, cycling its entire ATP pool many times per minute, and that turnover depends on an intact NAD+/NADH couple to sustain glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation. Because the same molecule powers both metabolism and stress-response signaling, changes in its abundance can reverberate across bioenergetics, gene regulation, and DNA repair at once.¹

Reviews of the field note that NAD+ pools tend to decline with normal aging, obesity, and hypertension — each an established cardiovascular risk factor — and that experimentally raising NAD+ improves outcomes across a spectrum of preclinical cardiomyopathy and heart-failure models.¹ That convergence is what makes NAD+ homeostasis a compelling object of study. It does not, on its own, establish that depletion causes human disease, a distinction this article returns to repeatedly.

What the failing human heart reveals about NAD+ status

The most direct human observations come from explanted or biopsied failing myocardium. Proteomic and acetylome analyses of human failing hearts have documented an increased NADH/NAD+ ratio and widespread mitochondrial protein hyperacetylation compared with nonfailing controls, a pattern also seen in mouse hearts undergoing pathological hypertrophy.² Hyperacetylation is informative because many mitochondrial enzymes are regulated by reversible lysine acetylation that NAD+-dependent deacetylases normally reverse; when NAD+ falls, that brake loosens.

Parallel work quantifying NAD+ biosynthetic enzymes found a roughly 30% loss of myocardial NAD+ in mouse dilated cardiomyopathy and pressure-overload models, accompanied by reduced expression of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting salvage enzyme. Critically, the same shift in biosynthetic enzyme expression was observed in human failing-heart biopsies relative to nonfailing controls.³ Studies of peripheral blood mononuclear cells from patients with advanced heart failure add another layer, linking systemic NAD+ status to reduced mitochondrial respiratory capacity and elevated inflammatory cytokine expression.⁵

These are correlative findings. They establish that NAD+-related derangements travel with human heart failure, but observational data cannot separate a depleted NAD+ pool that helps drive dysfunction from one that simply reflects a sick, energy-starved organ. Resolving that ambiguity requires controlled manipulation, which is where animal models enter.

How altered NAD+ homeostasis is linked to maladaptive remodeling

Maladaptive remodeling — the structural and molecular reorganization of the heart under chronic stress — is the phenotype most often connected to NAD+ decline in experimental systems. The proposed logic runs through metabolic inflexibility: reduced NAD+ availability constrains oxidative phosphorylation, nudging cardiomyocytes toward less efficient substrate use under sustained load, and the resulting energy deficit is thought to feed contractile decline, interstitial fibrosis, and chamber enlargement.¹

Across experimental hearts, the changes associated with disrupted NAD+ handling cluster at several levels:

• Depressed oxidative phosphorylation with reduced phosphocreatine-to-ATP ratios in stressed myocardium.¹
• Mitochondrial protein hyperacetylation that impairs the malate–aspartate shuttle and sensitizes the permeability transition pore.²
• Interstitial fibrosis and cardiomyocyte hypertrophy alongside progressive ventricular dilatation in NAD+-depleted models.³

In the dilated-cardiomyopathy model driven by cardiac serum response factor depletion, restoring NAD+ with the precursor nicotinamide riboside attenuated the progression of heart failure and stabilized myocardial NAD+ levels, with a more robust effect in dilated cardiomyopathy than in pressure overload.³ That a precursor intervention alters the remodeling trajectory is the kind of result that moves NAD+ from correlate toward candidate determinant — within rodents.

Sirtuins, PARPs, and CD38: the NAD+-consuming enzymes

If NAD+ depletion matters, the enzymes that consume it are the mechanistic hinge. Three families dominate cardiovascular NAD+ turnover, and each has been studied as both a cause and a consequence of redox imbalance.

Sirtuins

Sirtuins are NAD+-dependent deacylases whose activity falls when NAD+ becomes scarce. In endothelial and cardiac cells, reduced SIRT1 and SIRT6 activity is associated with altered chromatin regulation and diminished nitric oxide bioavailability, changes that experimental work connects to endothelial senescence and accelerated atherosclerotic processes.¹ Mitochondrial SIRT3 is a distinct case: when its activity drops, antioxidant and metabolic enzymes remain hyperacetylated. Cellular studies of hypertrophied cardiomyocytes have tied a weakened SIRT3–superoxide dismutase 2 interaction, and acetylation of SOD2 at lysine-68, to increased mitochondrial reactive oxygen species and hypertrophy.⁷

PARPs

Poly(ADP-ribose) polymerases, chiefly PARP1, are activated by DNA strand breaks and cleave NAD+ to build ADP-ribose polymers as a repair signal. Under mild damage this is protective, but extensive oxidative or inflammatory injury can drive PARP1 into overactivation that rapidly drains cellular NAD+ and, with it, the substrate for glycolysis and mitochondrial electron transport. Reviews of PARP biology in atherosclerosis, myocardial ischemia–reperfusion, and heart failure describe this depletion as a direct link between genomic stress and energetic collapse, with PARP inhibition preserving myocardial NAD+ and ATP in preclinical injury models.⁶

CD38

CD38 is the principal NAD+-degrading glycohydrolase in many mammalian tissues, and its expression rises with age. In an angiotensin II model of vascular remodeling, CD38 deficiency or NAD+ supplementation mitigated vascular smooth muscle cell senescence and reduced media thickening, implicating CD38-driven NAD+ decline in the senescence and remodeling of the vessel wall.⁴ Together these three families explain how a shrinking NAD+ pool and its consumers reinforce one another under chronic stress.⁸

Preclinical models that probe causality

Causal claims in this field rest largely on rodent experiments that manipulate NAD+ directly and observe the consequences. Loss-of-function approaches — genetic reduction of NAMPT or pharmacological salvage-pathway inhibition — consistently lower myocardial NAD+ and worsen metabolic and structural phenotypes under stress. Gain-of-function approaches restore NAD+ through salvage-pathway stimulation or precursor feeding.

The strongest logical structure comes from rescue experiments, where lowering NAD+ produces a phenotype and restoring NAD+ reverses or attenuates it. Elevating NAD+ by stimulating the salvage pathway suppressed mitochondrial protein hyperacetylation and cardiac hypertrophy and improved function under stress in mice, satisfying the bidirectional test.² Precursor supplementation with nicotinamide riboside similarly stabilized NAD+ and slowed heart-failure progression in a dilated-cardiomyopathy model.³ The most commonly used experimental systems are summarized below.

Mitochondrial and redox dysfunction downstream of NAD+ loss

The proposed downstream consequences of NAD+ depletion converge on the mitochondrion. Because NAD+ and NADH shuttle electrons into the respiratory chain, a shrunken or over-reduced pool destabilizes electron transport efficiency and can increase electron leak, amplifying reactive oxygen species generation.¹ Three interacting mechanisms are described in the literature.

1. Consumer-driven collapse

Excess activation of PARP1 and CD38 during oxidative stress accelerates NAD+ consumption, and in preclinical settings this coincides with loss of mitochondrial membrane potential and intensified redox imbalance in cardiomyocytes and endothelial cells.⁶

2. SIRT3 dysregulation

When NAD+ falls, mitochondrial SIRT3 activity is suppressed and antioxidant enzymes such as SOD2 remain acetylated and less active, weakening superoxide detoxification and allowing ROS to accumulate in cardiac mitochondria.⁷

3. Substrate-selective energetic failure

Mitochondrial fuel selection is also affected. Because the NAD+/NADH couple is central to the malate–aspartate shuttle and cytosolic redox transfer, hyperacetylation of shuttle proteins under NAD+ imbalance impairs the oxidation of cytosolic NADH and shifts the cellular redox state toward an energy deficit.² Restoring NAD+ balance, genetically or pharmacologically, reversed several of these mitochondrial defects in the same experimental hearts.² Mitochondrial-derived peptides such as MOTS-C are studied separately as tools for probing mitochondrial metabolic signaling in cell and rodent models.

How strong is the evidence, really?

Read as a whole, the literature offers a coherent mechanistic story with uneven levels of proof. The human data are almost entirely observational: hyperacetylation, altered NAD+/NADH ratios, and NAMPT downregulation are reproducibly seen in failing myocardium, but they describe a state, not a sequence of cause and effect.²³ The causal weight comes from rodent models, where NAD+ can be lowered and restored on demand and the heart responds accordingly.¹ Translation is the open question: species differences in NAD+ metabolism, the modest size of early human precursor trials, and the difficulty of measuring tissue NAD+ noninvasively all limit confident extrapolation.⁵⁸ For researchers, the productive framing is that NAD+ homeostasis is a well-supported experimental target whose clinical relevance remains to be demonstrated.

Research reagents for NAD+ pathway studies

Investigations of NAD+ biology depend on well-characterized reagents, because batch-to-batch variability and uncertain identity are common sources of irreproducibility in metabolic and redox experiments. Qovigen supplies analytically documented compounds, including NAD+, with transparent specifications and batch traceability intended to support consistency across cardiovascular research models. All materials are provided for laboratory research use only, and none of the associations described above should be read as a health claim.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.